Insmed Incorporated Common Stock INSM
i
Market dataready · fetched 2026-11-04T06:34:09.111Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T23:23:19.48822641Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-04T06:34:08.839561+00:00
Insmed Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 116.34 | 52.9% | 12.0% | 95.74 | 57.4% | 10.3% |
| 25Δ | 114.06 | 52.2% | 10.2% | 97.39 | 60.1% | 9.3% |
| 30Δ | 112.03 | 50.6% | 8.6% | 99.02 | 63.0% | 8.4% |
| 35Δ | 110.00 | 49.0% | 7.0% | 100.70 | 62.2% | 7.3% |
| 40Δ | 108.57 | 47.0% | 6.1% | 102.44 | 55.9% | 5.9% |
| 45Δ | 107.15 | 45.0% | 5.1% | 104.18 | 49.6% | 4.5% |
| 50Δ | 105.72 | 43.1% | 4.1% | 105.74 | 46.9% | 3.6% |
| 55Δ | 104.26 | 43.9% | 3.4% | 107.13 | 47.3% | 3.1% |
| 60Δ | 102.75 | 47.7% | 3.1% | 108.52 | 47.8% | 2.6% |
| 65Δ | 101.24 | 51.5% | 2.8% | 109.92 | 48.2% | 2.1% |
| 70Δ | 99.74 | 54.2% | 2.5% | 112.01 | 50.4% | 1.7% |
| 75Δ | 98.27 | 52.3% | 1.9% | 114.15 | 52.7% | 1.4% |
| 80Δ | 96.59 | 51.3% | 1.4% | 117.32 | 56.9% | 1.1% |
20Δ
- Pseudo strike
- 116.34
- IV
- 52.9%
- B/E move
- 12.0%
- Pseudo strike
- 95.74
- IV
- 57.4%
- B/E move
- 10.3%
25Δ
- Pseudo strike
- 114.06
- IV
- 52.2%
- B/E move
- 10.2%
- Pseudo strike
- 97.39
- IV
- 60.1%
- B/E move
- 9.3%
30Δ
- Pseudo strike
- 112.03
- IV
- 50.6%
- B/E move
- 8.6%
- Pseudo strike
- 99.02
- IV
- 63.0%
- B/E move
- 8.4%
35Δ
- Pseudo strike
- 110.00
- IV
- 49.0%
- B/E move
- 7.0%
- Pseudo strike
- 100.70
- IV
- 62.2%
- B/E move
- 7.3%
40Δ
- Pseudo strike
- 108.57
- IV
- 47.0%
- B/E move
- 6.1%
- Pseudo strike
- 102.44
- IV
- 55.9%
- B/E move
- 5.9%
45Δ
- Pseudo strike
- 107.15
- IV
- 45.0%
- B/E move
- 5.1%
- Pseudo strike
- 104.18
- IV
- 49.6%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- 105.72
- IV
- 43.1%
- B/E move
- 4.1%
- Pseudo strike
- 105.74
- IV
- 46.9%
- B/E move
- 3.6%
55Δ
- Pseudo strike
- 104.26
- IV
- 43.9%
- B/E move
- 3.4%
- Pseudo strike
- 107.13
- IV
- 47.3%
- B/E move
- 3.1%
60Δ
- Pseudo strike
- 102.75
- IV
- 47.7%
- B/E move
- 3.1%
- Pseudo strike
- 108.52
- IV
- 47.8%
- B/E move
- 2.6%
65Δ
- Pseudo strike
- 101.24
- IV
- 51.5%
- B/E move
- 2.8%
- Pseudo strike
- 109.92
- IV
- 48.2%
- B/E move
- 2.1%
70Δ
- Pseudo strike
- 99.74
- IV
- 54.2%
- B/E move
- 2.5%
- Pseudo strike
- 112.01
- IV
- 50.4%
- B/E move
- 1.7%
75Δ
- Pseudo strike
- 98.27
- IV
- 52.3%
- B/E move
- 1.9%
- Pseudo strike
- 114.15
- IV
- 52.7%
- B/E move
- 1.4%
80Δ
- Pseudo strike
- 96.59
- IV
- 51.3%
- B/E move
- 1.4%
- Pseudo strike
- 117.32
- IV
- 56.9%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 49.40% | |
| 44.55% | |
| 44.33% | |
| 45.02% | |
| 43.28% | |
| 43.13% | |
| 44.22% | |
| 46.77% | |
| 45.32% | |
| 44.70% | |
| 52.57% | |
| 43.45% | |
| 44.67% | |
| 42.52% | |
| 41.68% | |
| 41.53% | |
| 42.33% | |
| 42.85% | |
| 41.57% | |
| 42.24% | |
| 42.20% | |
| 42.91% | |
| 45.24% | |
| 46.83% | |
| 46.49% | |
| 46.92% | |
| 46.55% | |
| 47.54% | |
| 54.03% | |
| 55.54% | |
| 49.67% | |
| 50.02% | |
| 50.02% | |
| 50.66% | |
| 52.80% | |
| 52.43% | |
| 52.97% | |
| 51.18% | |
| 52.84% | |
| 53.89% | |
| 55.12% | |
| 55.83% | |
| 59.39% | |
| 59.55% | |
| 58.19% | |
| 58.03% | |
| 59.04% | |
| 61.10% | |
| 61.48% | |
| 68.07% | |
| 58.95% | |
| 58.47% | |
| 59.01% | |
| 58.56% | |
| 58.40% | |
| 57.94% | |
| 59.65% | |
| 61.69% | |
| 67.81% | |
| 48.17% | |
| 44.37% |
Biotechnology
INVA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
More →IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Description unavailable
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →IRD
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge…
More →IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious…
More →